Metrion Biosciences Appoints Dr Chris Mathes as Chief Commercial Officer
23 July 2024 - 10:14AM
Business Wire
Appointment of experienced preclinical CRO
specialist to support accelerated expansion into key global
markets
Metrion Biosciences Ltd (“Metrion”), the specialist preclinical
contract research organisation (CRO) and a leader in ion channel
screening, today announced the appointment of Dr Chris Mathes, MBA,
as Chief Commercial Officer (CCO). Chris will work alongside the
Company’s expert leadership team to drive commercial strategy and
lead global business development and marketing activities.
Following completion of Metrion’s £3.7M equity financing in
December 20231, the Company has made several high-profile
appointments2. Chris’ appointment as CCO further strengthens the
senior management team, enhancing its scientific and commercial
capabilities, and continue to drive expansion in key global
markets.
Chris is a well-respected industry leader with over 25 years of
experience in the biopharmaceutical sector, specialising in the
preclinical CRO space and developing high-performance sales and
marketing strategies. He has held several executive-level
positions, at Sophion Bioscience, ChanTest (now part of Charles
River Laboratories), Icagen and AnaBios, where he provided
strategic support to guide business development and overall
strategy. Over the last few months Chris has also been advising
Metrion on business development in the USA.
Chris holds a PhD in Neuroscience from the University of
California, Los Angeles (UCLA) and an MBA from Rutgers University.
He completed his post-doctoral research at Stanford University and
the Max Planck Institute for Biophysical Chemistry, focussing on
ion channel research and patch clamp technology, and has published
17 peer-reviewed papers on his work.
Dr Andrew Southan, Chief Executive, Metrion Biosciences,
said: “Chris brings outstanding commercial and scientific
expertise to Metrion’s senior management team. His experience in
leading ion channel and preclinical drug discovery commercial
operations globally is second to none. Chris adds depth to our
neuroscience expertise, further strengthens our presence in the
USA, and I am confident he will make a substantial contribution
towards achieving Metrion’s vision of becoming the leading
preclinical ion channel service provider.”
Dr Chris Mathes, CCO, Metrion Biosciences, commented: “As
a specialised CRO, Metrion has an outstanding offering to support
preclinical drug discovery and safety pharmacology research. I am
excited to join the industry leading team, which also brings me
back to my ion channel and Neuroscience roots, and I look forward
to working toward the Company’s goal of partnering with leading
biopharma companies globally, connecting them to our capabilities,
assays and expertise that translate to greater success in clinical
trials.”
For more information: https://www.metrionbiosciences.com/.
- Press release (20th December, 2023) - Metrion Biosciences
Closes £3.7m New Equity Financing • Metrion Biosciences
- Press release (11th March, 2024) - Metrion Strengthens Team
With Three Key Appointments (metrionbiosciences.com)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723400611/en/
Media Contact Katie Odgaard Zyme Communications E-mail:
katie.odgaard@zymecommunications.com Tel: +44 (0)7787 502 947